For the third quarter of the fiscal year ending December 2026, consolidated results were: net sales of 9,943 million yen (Year-over-Year +6.9%), operating income of 1,094 million yen (YoY +15.8%), ordinary income of 1,168 million yen (YoY +23.7%), and quarterly net income attributable to owners of parent of 687 million yen (YoY -32.2%). By segment, the Thermal segment remained strong due to expanding semiconductor demand. Conversely, the Medical segment declined significantly due to the termination of contract manufacturing. The full-year forecast remains unchanged.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"6870","jir_company_name":"Fenwal Controls of Japan, Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/6870-20261030-01.pdf","jir_short_summary":"For the third quarter of the fiscal year ending December 2026, consolidated results were: net sales of 9,943 million yen (Year-over-Year +6.9%), operating income of 1,094 million yen (YoY +15.8%), ordinary income of 1,168 million yen (YoY +23.7%), and quarterly net income attributable to owners of parent of 687 million yen (YoY -32.2%). By segment, the Thermal segment remained strong due to expanding semiconductor demand. Conversely, the Medical segment declined significantly due to the termination of contract manufacturing. The full-year forecast remains unchanged.","jir_summary":"### Overview of Performance\nIn the third quarter of the fiscal year ending December 2026, consolidated net sales increased 6.9% year-over-year to 9,943 million yen. By segment, the Thermal segment contributed significantly due to a substantial rise in orders and shipments driven by expanding semiconductor demand. Meanwhile, the Medical segment saw a sharp decline due to the termination of contract manufacturing, resulting in a 32.2% year-over-year decrease in consolidated net income. From a financial perspective, both operating income and ordinary income showed growth compared with the prior year.\n\n### Outlook and Impact\nThe full-year forecast remains unchanged from the previously announced outlook, but the effects of matters such as the revocation of certification for gas fire suppression equipment containers continue to be examined. Demand for the Thermal segment is expected to continue due to increased investment in the semiconductor market, and the company will continue to pursue orders with an emphasis on profitability. As the Medical segment wind-down progresses, the company plans to drive growth through other segments.","jir_financial_highlights":"Net Sales: 9,943 million yen (YoY +6.9%)\nOperating Income: 1,094 million yen (YoY +15.8%)\nOrdinary Income: 1,168 million yen (YoY +23.7%)\nQuarterly Net Income Attributable to Owners of Parent: 687 million yen (YoY -32.2%)\nSegment Net Sales (Thermal Segment): 2,622 million yen (YoY +69.8%)\nSegment Net Sales (Medical Segment): 608 million yen (YoY -40.4%)","jir_category":"","jir_hashtags":"#FenwalControlsOfJapan, #FinancialSummary","jir_key_figures":"Net Sales: 9,943 million yen (YoY +6.9%)\nOperating Income: 1,094 million yen (YoY +15.8%)\nQuarterly Net Income Attributable to Owners of Parent: 687 million yen (YoY -32.2%)","jir_meta_title":"Fenwal Controls of Japan, Ltd. \u2014 Third Quarter Financial Summary for FY Dec 2026 | Net Sales 9,943 million yen (+6.9% YoY)","jir_meta_description":"Key points from Fenwal Controls of Japan, Ltd.'s third quarter financial summary for the fiscal year ending December 2026: net sales, operating income, and ordinary income increased while net income decreased. Includes segment trends and full-year outlook.","jir_og_title":"Key Points of Fenwal Controls of Japan, Ltd. Third Quarter Financial Results","jir_og_description":"Fenwal Controls of Japan, Ltd. reported increased net sales with a strong Thermal segment, while the Medical segment declined significantly. Summary of outlook and key takeaways.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":58953,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-138987","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n